

Åmer KÃ¼Å§Ã¼k

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4671996/publications.pdf>

Version: 2024-02-01

64
papers

1,041
citations

471371

17
h-index

477173

29
g-index

66
all docs

66
docs citations

66
times ranked

1716
citing authors

#	ARTICLE	IF	CITATIONS
1	Lycopene in Cancer Prevention and Treatment. American Journal of Therapeutics, 2008, 15, 66-81.	0.5	80
2	Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab. Clinical Genitourinary Cancer, 2018, 16, e563-e575.	0.9	72
3	Acetylation of KLF5 maintains EMT and tumorigenicity to cause chemoresistant bone metastasis in prostate cancer. Nature Communications, 2021, 12, 1714.	5.8	70
4	Effects of genistein supplementation on genome-wide DNA methylation and gene expression in patients with localized prostate cancer. International Journal of Oncology, 2017, 51, 223-234.	1.4	61
5	Orally Administered Lycopene Attenuates Diethylnitrosamine-Induced Hepatocarcinogenesis in Rats by Modulating Nrf-2/HO-1 and Akt/mTOR Pathways. Nutrition and Cancer, 2014, 66, 590-598.	0.9	50
6	Soy Isoflavones in Integrative Oncology: Increased Efficacy and Decreased Toxicity of Cancer Therapy. Integrative Cancer Therapies, 2019, 18, 153473541983531.	0.8	43
7	Lycopene and Chemotherapy Toxicity. Nutrition and Cancer, 2010, 62, 988-995.	0.9	40
8	Impact of ¹⁸ F-Fluciclovine PET on Target Volume Definition for Postprostatectomy Salvage Radiotherapy: Initial Findings from a Randomized Trial. Journal of Nuclear Medicine, 2017, 58, 412-418.	2.8	36
9	Genistein Prevents Development of Spontaneous Ovarian Cancer and Inhibits Tumor Growth in Hen Model. Cancer Prevention Research, 2019, 12, 135-146.	0.7	36
10	IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)., 2021, 9, e002903.		36
11	Carotenoids and non-alcoholic fatty liver disease. Hepatobiliary Surgery and Nutrition, 2015, 4, 161-71.	0.7	36
12	Soy foods, isoflavones, and breast cancer. Cancer, 2017, 123, 1901-1903.	2.0	34
13	TGF-β ² causes Docetaxel resistance in Prostate Cancer via the induction of Bcl-2 by acetylated KLF5 and Protein Stabilization. Theranostics, 2020, 10, 7656-7670.	4.6	34
14	Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Oncologist, 2020, 25, e484-e491.	1.9	29
15	External validation of the modified Glasgow prognostic score for renal cancer. Indian Journal of Urology, 2014, 30, 33.	0.2	26
16	A Novel Flavonoid Composition Targets Androgen Receptor Signaling and Inhibits Prostate Cancer Growth in Preclinical Models. Neoplasia, 2018, 20, 789-799.	2.3	23
17	Centrosome amplification: a quantifiable cancer cell trait with prognostic value in solid malignancies. Cancer and Metastasis Reviews, 2021, 40, 319-339.	2.7	22
18	Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer. Theranostics, 2021, 11, 6873-6890.	4.6	21

#	ARTICLE	IF	CITATIONS
19	Repositioning Dopamine D2 Receptor Agonist Bromocriptine to Enhance Docetaxel Chemotherapy and Treat Bone Metastatic Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1859-1870.	1.9	19
20	Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors. <i>Frontiers in Oncology</i> , 2021, 11, 707050.	1.3	19
21	Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2021, 26, 1017-1025.	1.9	18
22	Tomato powder impedes the development of azoxymethane-induced colorectal cancer in rats through suppression of COX-2 expression via NF- κ B and regulating Nrf2/HO-1 pathway. <i>Molecular Nutrition and Food Research</i> , 2012, 56, 1477-1481.	1.5	16
23	Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2021, 26, 397-405.	1.9	14
24	Modulation of inflammation by phytochemicals to enhance efficacy and reduce toxicity of cancer chemotherapy. <i>Critical Reviews in Food Science and Nutrition</i> , 2023, 63, 2494-2508.	5.4	14
25	Time-dependent effects of prognostic biomarkers of systemic inflammation in patients with metastatic renal cell carcinoma. <i>Tumor Biology</i> , 2017, 39, 101042831770551.	0.8	13
26	A novel preoperative inflammatory marker prognostic score in patients with localized and metastatic renal cell carcinoma. <i>Asian Journal of Urology</i> , 2017, 4, 230-238.	0.5	13
27	Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors. <i>Cancer Medicine</i> , 2020, 9, 2752-2760.	1.3	13
28	Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors. , 2021, 9, e002851.		12
29	Lycopene in the Prevention of Radiation-Induced Esophagitis. <i>Nutrition and Cancer</i> , 2017, 69, 319-329.	0.9	10
30	Small molecule BKM1972 inhibits human prostate cancer growth and overcomes docetaxel resistance in intraosseous models. <i>Cancer Letters</i> , 2019, 446, 62-72.	3.2	10
31	Epigenetic alterations and genetic variations of angiotensin-converting enzyme 2 (ACE2) as a functional receptor for SARS-CoV-2: potential clinical implications. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 1587-1598.	1.3	10
32	Cancer biomarkers. <i>Molecular Aspects of Medicine</i> , 2015, 45, 1-2.	2.7	9
33	Tomato Powder Modulates NF- κ B, mTOR, and Nrf2 Pathways during Aging in Healthy Rats. <i>Journal of Aging Research</i> , 2019, 2019, 1-8.	0.4	9
34	Effect of Increasing Levels of Web-Based Behavioral Support on Changes in Physical Activity, Diet, and Symptoms in Men With Prostate Cancer: Protocol for a Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2018, 7, e11257.	0.5	9
35	Bladder preserving chemoradiotherapy compared to surgery for variants of urothelial carcinoma and other tumors types involving the bladder: An analysis of the National Cancer Database. <i>Clinical and Translational Radiation Oncology</i> , 2021, 26, 30-34.	0.9	8
36	Inhibition of skeletal growth of human prostate cancer by the combination of docetaxel and BKM1644: an aminobisphosphonate derivative. <i>Oncotarget</i> , 2016, 7, 27489-27498.	0.8	8

#	ARTICLE	IF	CITATIONS
37	Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment Options. <i>Oncologist</i> , 2021, 26, 956-964.	1.9	7
38	The addition of chemotherapy in the definitive management of high risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 475-487.	0.8	6
39	Baseline basophil and basophil-to-lymphocyte status is associated with clinical outcomes in metastatic hormone sensitive prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 271.e9-271.e18.	0.8	6
40	Cetuximab and methotrexate in recurrent or metastatic head and neck squamous cell carcinomaâ€”A single institution analysis of 54 patients. <i>Clinical Otolaryngology</i> , 2019, 44, 639-643.	0.6	5
41	Utility of the modified Glasgow prognostic score in patients with metastatic renal cell carcinoma treated with targeted agents.. <i>Journal of Clinical Oncology</i> , 2012, 30, 441-441.	0.8	5
42	Neoadjuvant Cabozantinib in an Unresectable Locally Advanced Renal Cell Carcinoma Patient Leads to Downsizing of Tumor Enabling Surgical Resection: A Case Report. <i>Frontiers in Oncology</i> , 2020, 10, 622134.	1.3	4
43	Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade. <i>Frontiers in Oncology</i> , 2021, 11, 701345.	1.3	4
44	Mifepristone Has Limited Activity to Enhance the In Vivo Efficacy of Docetaxel and Enzalutamide Against Bone Metastatic and Castration-Resistant Prostate Cancer. <i>Anticancer Research</i> , 2017, 37, 6235-6243.	0.5	4
45	Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 53-59.	0.9	4
46	Expression of Nectin-4 and PD-L1 in bladder cancer with variant histology.. <i>Journal of Clinical Oncology</i> , 2022, 40, 529-529.	0.8	4
47	Overcoming prostate cancer drug resistance with a novel organosilicon small molecule. <i>Neoplasia</i> , 2021, 23, 1261-1274.	2.3	4
48	Novel smallâ€”molecule LG1836 inhibits the in vivo growth of castrationâ€”resistant prostate cancer. <i>Prostate</i> , 2020, 80, 993-1005.	1.2	2
49	Novel risk scoring system for metastatic renal cell carcinoma patients treated with cabozantinib. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100393.	0.7	2
50	Sites of metastases (mets) and their association with clinical outcomes (CO) in urothelial cancer patients (pts) treated with immunotherapy (IO).. <i>Journal of Clinical Oncology</i> , 2019, 37, 473-473.	0.8	2
51	Is vitamin A an antioxidant?. <i>International Journal for Vitamin and Nutrition Research</i> , 2022, , .	0.6	2
52	Small-Cell Carcinoma of the Prostate: Report of Outcomes of Localized Disease Using the National Cancer Database. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e193-e199.	0.9	1
53	255â€”Efficacy of sequential immune checkpoint inhibition (ICI) in patients with genitourinary malignancies. , 2020, 8, A277-A278.		1
54	Association of baseline modified Glasgow Prognostic Score (mGPS) with survival outcomes in patients with metastatic urothelial cell carcinoma (mUCC) treated with immune checkpoint inhibitors (CPI).. <i>Journal of Clinical Oncology</i> , 2020, 38, 563-563.	0.8	1

#	ARTICLE	IF	CITATIONS
55	Association of modified Glasgow Prognostic Score (mGPS) with survival outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (CPI).. Journal of Clinical Oncology, 2020, 38, 738-738.	0.8	1
56	Exploratory study of F-fluciclovine pet/ct for response assessment to docetaxel in patients with metastatic castration-resistant prostate cancer. American Journal of Nuclear Medicine and Molecular Imaging, 2021, 11, 218-229.	1.0	1
57	Combination Immune Checkpoint Blockade Regimens for Previously Untreated Metastatic Renal Cell Carcinoma: The Winship Cancer Institute of Emory University Experience. Journal of Immunotherapy and Precision Oncology, 2022, , .	0.6	1
58	Genistein Protects Against DNA Damage in Hematopoietic Stem Cells,. Blood, 2011, 118, 3437-3437.	0.6	0
59	Genistein Protects Hematopoietic Stem Cells Against G-CSF Induced DNA Damage. Blood, 2012, 120, 3486-3486.	0.6	0
60	A novel preoperative inflammatory marker prognostic score in patients with clear cell renal cell carcinoma.. Journal of Clinical Oncology, 2016, 34, 566-566.	0.8	0
61	Biomarker study of early death in patients with intermediate and favorable risk metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2017, 35, 530-530.	0.8	0
62	EDITORIAL COMMENT. Urology, 2021, 156, 209-210.	0.5	0
63	A risk scoring system for African-American (AA) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line abiraterone (ABA) or enzalutamide (ENZ).. Journal of Clinical Oncology, 2020, 38, 51-51.	0.8	0
64	Clinical outcomes in advanced urothelial cancer (UC) patients who experienced immune-related adverse events (irAEs) after immune checkpoint inhibitor monotherapy (ICI).. Journal of Clinical Oncology, 2022, 40, 544-544.	0.8	0